Development of new agents with modern techniques to monitor immunosuppressant activity has made significant progress.28 The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus involve a class of drugs suppressing T cell proliferation and reducing tumor growth. Here, MTOR is linked to neoplasm.